Pakatip Ruenraroengsak

Mahidol University, Thailand

Title: Dual delivery of doxorubicin and plant-based compounds from Mangifera indica L. for synergistic cancer therapy against hepatocellular carcinoma

---

Biography

.

Abstract

Plant-based compounds have been used as alternative anticancer drugs or adjuvant therapy together with chemo-drugs without testing for their anticancer activities, toxicity and drug interaction. Here anticancer activities of 7 potential plants including Quercus infectoria Oliver. (QI), Ardisia pendulifera Pit. (AP), Mangifera indica L. (MI), Houttuynia cordata Thunb. (HC), Acanthopanax trifoliatus Merr. (AT), Tiliacora triandra (Colebr.) Diels (TT), and Eclipta prostrata L. (EP) were tested against human hepatocellular carcinoma (HepG2) cell line. MI and AP extracts exhibited the highest anticancer activities among all extracts with IC50 at 595.84 ± 9.12, 188.79 ± 8.97 ?g/mL, respectively. A co-delivery system of mesoporous silica nanoparticles (MSNs) was developed using doxorubicin (DOX) and MI extract as model drugs. DOX encapsulated MSNs (DOX-MSNs) with diameter of 221.3 ± 2.6 nm offered % encapsulation efficiency (%EE) and %loading capacity (%LC) at 96.4 ± 2.5 % and 29.0 ± 0.7 %, respectively. MI-MSNs with diameter of 226.0 ± 1.0 nm offered %EE and %LC at 97.1± 1.0 % and 28.6 ± 0.3%, respectively. Anticancer activity of the co-delivery was evaluated using DOX:MI at 1 to 1 ratio with the concentration ranges between 5.93 - 50.33 ?g/mL (0.1IC50-1IC50) of DOX and between 74.48-595.84 ?g/mL (0.1IC50-1IC50) of MI extract. The co-delivery of ratio 11.98 ?g/mL of DOX: 74.48 ?g/mL of MI exhibited the highest inhibitory effect at 80.0 ± 2.9%, while the co-delivery using DOX-MSN:MI-MSN at the same concentration ratio significantly inhibited (**p<0.01, n=3) HepG2 cells up to 89.2 ± 2.3 % indicating that a significant synergistic anticancer efficacy could be enhanced by MSNs.